You are here: Industry Insights > inhibitors

News List

Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part one) Xiaomichong
July 09, 2024
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies characterized by defective normal hematopoiesis leading to a reduction in blood cells, with a risk of transformation into acute myeloid leukemia.
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity WND
November 07, 2023
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
Drug Marketing in China and Worldwide (August)(2023) PharmaSources
September 01, 2023
The official website shows that the drugs developed by major companies have been declared for marketing.
Are the Fourth Generation EGFR Inhibitors the Next Wealth Creation Myth? PharmaSources/Yefenghong
April 18, 2022
Junshi Biosciences WJ13404 Has Been Submitted for Clinical Application
Weekly Pharmaceutical News Review of PharmaSources.com (January 4th to 7th) PharmaSources/Caicai
January 17, 2022
The new review this week is from January 4 to 7, covering a total of 18 pieces of information in 4 sections, i.e. review, policy, listing, and others.
Global Diabetes Market Outlook Dr. Preet Pal S.B.
November 22, 2021
Diabetes is a well-known metabolic disorder, and the number of people living with it continues to rise. Although it is a segment of opportunity for pharmaceutical manufacturers, understanding it is complex.
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients prnasia
February 15, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide...
FLIP sync: Collaboration for inhibitors and cancer treatments pharmatimes
January 26, 2022
Ipsen and Domainex collaboration will provide an exclusive licence to develop innovative inhibitors and pioneering cancer treatments.
Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers prnasia
January 24, 2022
Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118...
Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) prnasia
January 20, 2022
The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.

Previous page 1 2 3 Next page